The assessment of cysteinyl leukotriene receptor antagonist role in inhibition of atherosclerosis, proliferation and its influence on endothelial function in patients undergoing endovascular treatment due to peripheral arterial disease.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511894-32-00

Acronym

CADET-PAD

Enrollment

200

Registered

2024-07-01

Start date

2021-08-19

Completion date

Unknown

Last updated

2024-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemia of the lower limbs in the course of obstructive artery disease

Brief summary

Restenosis in a previously treated artery

Detailed description

MACE, high lower limb amputation, significant loss in quality of life

Interventions

DRUGlactose monohydrate - 100

DRUG00 mg/tablet cellulose microcrystalline - 95

DRUG60 mg/tablet Croscarmellose sodium - 2

DRUG00 mg/tablet Magnesium stearate - 2

DRUG40 mg/tablet table coating - OPADRY 20A82938 Yellow - COLORCON

DRUGAsmenol

DRUG10 mg

DRUGtabletki powlekane

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Restenosis in a previously treated artery	—

Secondary

Measure	Time frame
MACE, high lower limb amputation, significant loss in quality of life	—

Countries

Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026